Targeting ferroptosis resistance resensitizes metastatic HR + HER2 − breast cancer cells to palbociclib‐hormone therapy

Abstract excerpt

Metastatic hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2−) breast cancer often develops resistance to first-line treatment, typically combining cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) with hormone therapy (HT) [1, 2]. After an initial response, most patients become resistant, and compensatory mechanisms are not fully uncovered [3]. To address this, we...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Cancer Genomics and Diagnostics
• Share to Cancer-related Molecular Pathways